comprehensive evaluation of tumor oxygenation, metabolism and blood supply of high grade glioma and cervical cancers using dynamic faza pet and multiparametric mr

Conditions: Brain Tumor; Cervical Cancer

Summary: primary objectives to investigate the relationship between dynamic mri, brain tumor perfusion (dsc) and permeability (dce), and dynamic 18f-faza pet uptake. secondary objectives to investigate the relationship between tumors with greater hypoxia defined by qbold and 18f-faza pet and pathological features including proportionate necrosis, ki-67 and idh mutation status to investigate the correlation between the hypoxic tumor region delineated using 18f-faza pet and qbold


Eligibility criteria:
inclusion criteria: glioma cohort * adult (\> 18 years old) patients with newly diagnosed or recurrent high grade glioma with newly confirmed pathology (within 1 month) * able to provide informed consent * no contraindications to mri with gadolinium contrast or 18f-faza pet cervical cohort * adult (\>18 years old) female with newly diagnosed cervical cancer * able to provide informed consent * receiving surgery, radiotherapy or chemotherapy * no contraindication to mri with gadolinium contrast or 18f-faza pet exclusion criteria: glioma cohort * prior nephrectomy or planned nephrectomy. * prior brain radiation within 30 days. * pregnant or lactating women: pregnant women are excluded from this study because the effects of 18f-faza in pregnancy are not known. a urine or serum pregnancy test will be performed before enrollment after informed consent is obtained. the pregnancy test is part of soc before imaging. * lactation should be suspended for at least two days following the administration of 18f-faza to the mother, because of the unknown but potential risk for adverse events in nursing infants secondary to administration of the radionuclide to a lactating woman. * subjects with contraindications to the use of 18f-faza including confirmed allergy. * patients with a body weight of 400 pounds or more, or a bmi which precludes their entry into the bore of the pet-mri scanner, because the findings will probably be compromised in image quality with pet-mri. * any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator may significantly interfere with study compliance. cervical cohort * prior nephrectomy or planned nephrectomy. * pregnant or lactating women: pregnant women are excluded from this study because the effects of 18f-faza in pregnancy are not known. a urine or serum pregnancy test will be performed before enrollment after informed consent is obtained. the pregnancy test is part of soc before imaging. * lactation should be suspended for at least two days following the administration of 18f-faza to the mother, because of the unknown but potential risk for adverse events in nursing infants secondary to administration of the radionuclide to a lactating woman. * subjects with contraindications to the use of 18f-faza including confirmed allergy. * patients with a body weight of 400 pounds or more, or a bmi which precludes their entry into the bore of the pet-mri scanner, because the findings will probably be compromised in image quality with pet-mri and mri. * any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator may significantly interfere with study compliance.